The severity of the HIV epidemic and limits on prevention and treatment resources have forced planners and providers to make difficult choices about which interventions to implement to prevent and treat HIV and substance abuse. The goal of our project is to evaluate existing and potential HIV and substance abuse interventions to provide critical information on effectiveness, public-health impact, and efficiency. This project aims to promote reasoned planning and policy making in the realm of HIV and substance abuse prevention and treatment via the development of mathematical and economic models. To achieve this goal, we have the following specific aims: 1. To estimate production functions that characterize the relationship between program expenditures and health outcomes, such as reductions in risky behaviors for prevention programs and delivery of services for treatment programs 2. To develop model-based methods of translating the behavioral impact of HIV-related interventions into epidemiologically meaningful outcome measures, such as years of life saved. 3. To determine how best to estimate health outcomes, economic outcomes, and cost effectiveness of HIV and substance abuse interventions. 4. To assess the effectiveness and cost-effectiveness of specific interventions aimed at preventing and treating HIV and substance abuse. 5. To inform the allocation of societal resources by examining the effectiveness and cost effectiveness of portfolios of prevention and treatment interventions. This work includes analyzing national and international HIV prevention and treatment strategies, and assessing how to balance HIV prevention and treatment interventions to achieve the greatest health benefit. 6. To examine the relationship between policy modeling and public health decision making in the areas of HIV and substance abuse - in particular, to explore how to make analyses most useful to policy makers. The proposed research will advance the state of the art in HIV planning and policy modeling, critically evaluate promising interventions, and help provide the scientific foundation for allocation of scarce resources to portfolios of HIV and substance abuse prevention and treatment interventions.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA015612-10
Application #
8094334
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Hartsock, Peter
Project Start
2002-09-25
Project End
2013-04-30
Budget Start
2011-07-01
Budget End
2013-04-30
Support Year
10
Fiscal Year
2011
Total Cost
$606,039
Indirect Cost
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Reddy, Krishna P; Kong, Chung Yin; Hyle, Emily P et al. (2017) Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States. JAMA Intern Med 177:1613-1621
Gonsalves, Gregg S; Paltiel, A David; Cleary, Paul D et al. (2017) A Flow-Based Model of the HIV Care Continuum in the United States. J Acquir Immune Defic Syndr 75:548-553
Walensky, Rochelle P; Borre, Ethan D; Bekker, Linda-Gail et al. (2017) Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid. Ann Intern Med 167:618-629
Liu, Shan; Brandeau, Margaret L; Goldhaber-Fiebert, Jeremy D (2017) Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment. Health Care Manag Sci 20:16-32
Suen, Sze-Chuan; Brandeau, Margaret L; Goldhaber-Fiebert, Jeremy D (2017) Optimal timing of drug sensitivity testing for patients on first-line tuberculosis treatment. Health Care Manag Sci :
Suen, Sze-Chuan; Goldhaber-Fiebert, Jeremy D; Brandeau, Margaret L (2017) Risk stratification in compartmental epidemic models: Where to draw the line? J Theor Biol 428:1-17
Glaubius, Robert L; Hood, Greg; Penrose, Kerri J et al. (2016) Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa. Clin Infect Dis 63:539-47
Chahal, Harinder S; Marseille, Elliot A; Tice, Jeffrey A et al. (2016) Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med 176:65-73
Gilbert, Jennifer A; Shenoi, Sheela V; Moll, Anthony P et al. (2016) Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa. PLoS One 11:e0165614
Bendavid, Eran (2016) Past and Future Performance: PEPFAR in the Landscape of Foreign Aid for Health. Curr HIV/AIDS Rep 13:256-62

Showing the most recent 10 out of 135 publications